465 results about "Human cell" patented technology

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human carbohydrate antigen CA125 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The monoclonal antibody provided by the invention can specifically recognize and bind to a natural carbohydrate antigen CA125 expressed by human cells or tissues, has good affinity and relatively high sensitivity of binding of the antibody and the antigen, has strong anti-interference ability to complex non-target protein components in the cells / tissues, is beneficial to significantly improving the accuracy and reliability of immunodetection of human CA125 protein, and has good application prospects. The method is suitable for high-specificity, high-sensitivity and high-reliability detection of the human CA125 protein, and has good applicability in a plurality of detection systems such as immunoblotting, immunoprecipitation, immunohistochemistry and the like.

The invention provides a grass carp sourced U6 promoter. The sequence of the grass carp sourced U6 promoter is shown as one of SEQ ID NO: 1-3. Three grass carp-derived U6 promoters are cloned, the transcriptional activity and cross-species adaptability of the three promoters are analyzed, results show that the three promoters can show transcriptional activity in fish cells and human cells, the transcriptional activity of ciU6-1 is remarkably higher than that of the other two promoters, heterologous DNA can be transcribed in various cells, and the expression of the ciU6-1 in the fish cells and the human cells is improved. And the method can be used for gene editing means based on Cas9.

The present disclosure provides compositions and methods for the targeted modification of RNA molecules by RNA prime editing. The compositions and methods may be conducted invitro or in vivo within cells (e.g., human cells) for the therapeutic correction of disease-causing mutations and / or installation of motifs or mutations in RNA molecules of interest as a tool for scientific research. The disclosure provides compositions and methods for conducting RNA prime editing of a target RNA molecule (e.g., an RNA transcript) that enables the incorporation of one or more nucleotide changes and / or targeted mutagenesis of a target RNA molecule. The nucleotide change can include a single-nucleotide change, an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides a variety of configurations of the RNA prime editors each comprising a nucleic acid programmable RNA binding proteins (napRNAbp), such as Cas13, and an RNA-dependent RNA polymerase (RDRP), which are provided as fusion proteins or which can be separately provided in trans. The RNA prime editors are guided to a target RNA site by a guide RNA, which can be a rpegRNA that includes a template region for the synthesis of an RNA sequence to be installed on the RNA molecule attached to an available 3′ terminus. In others embodiments, the RNA template can be provided in trans.

Disclosed are compositions comprising a nucleic acid molecule. The nucleic acid molecule may encode an exonic sequence or portion thereof of a target ribonucleic acid (RNA) sequence. The nucleic acid molecule may further encode one or more stabilization domains. The one or more stabilization domains may be configured to reduce a cellular nuclease activity compared to a nucleic acid molecule that does not comprise the one or more stabilization domains.

The present invention relates to a treatment of CCHFV infection, in particular CCFHV infection. Here, the inventors showed that antibody blocking LDL-R family at the surface of human cells could reduce CCHFV infection by 80%, such inhibition only occurred when blocking was performed prior to or at the time of infection though not at later time points. Furthermore, they found that incubation of viral particles with a soluble form of LDL-R could impair CCHFV infection. They found that ApoE antibodies could block CCHFV infectivity by up to 10-fold only when the viral particles were produced in cells that express ApoE. Thus, the present invention relates to an LDL-R family and / or an ApoE inhibitor for use in the prevention and / or the treatment of CCHFV infection in subjects in need thereof.

In some aspects, the disclosure provides humanized immunodeficient mouse models that support long term transplantation and function of human T cells, natural killer cells, and bone marrow cells without the need for conditioning.

Disclosed are AAV viral-based vector compositions useful in delivering a variety of nucleic acid segments, including those encoding therapeutic polypeptides to selected mammalian host cells for use in therapeutic autoimmune modalities, including, for example, the in vivo induction of immunological tolerance via a liver-directed AAV-based gene therapeutic regimen for treating and / or ameliorating autoimmune disorders such as multiple sclerosis. Further disclosed are nucleic acid segments encoding therapeutic polypeptides that have been codon-optimized for expression in human cells.

The present invention relates to an RNA capping enzyme comprising or consisting of an amino acid sequence having high identity with any of the sequences of SEQ ID NO: 1-28, which can be expressed in vitro, in human cells, in mouse cells or in yeast cells, and which has the activities of RNA 5 '-triphosphatase (RT), guanylate transferase (GT) and RNA guine-N7 methyltransferase (RNMT) at the same time. The invention also relates to a mutant obtained by carrying out substitution, addition and / or deletion of amino acid on any sequence in SEQ ID NO: 1-28, a nucleotide sequence for coding the capping enzyme and / or the mutant thereof, and an expression construct or a host cell containing the nucleotide sequence. The invention also relates to a composition comprising the capping enzyme as well as a method and a reaction system for capping RNA by using the capping enzyme, a mutant or a composition thereof.

System and method for providing biocompatible, nutrient filled media to the Human Cells, Tissues, and cellular and tissue-based Products (HCT / P) while removing wastes. The present teachings provide for sensing the characteristics of the media, and modifying the characteristics when necessary. The present teachings can also provide components that can provide fluid pumping integrated with fluid gas exchange, and sensing of fluid characteristics at consistent times during the fluid flow cycle. System and method control multiple bioreactors from a centralized media reservoir, while fluidically isolating the bioreactors from cross-contamination.

The invention provides a method and a system for detecting the chimeric rate of human cells based on a micro haploid, and belongs to the technical field of chimera analysis. According to the invention, the micro haploid is innovatively adopted as a basic unit of the genetic marker, and different from the prior art in which DNA fragments containing the genetic marker are generally enriched through a multiplex PCR amplification technology, a probe targeted capture technology is introduced for enrichment; the limitation of the multiple PCR amplification technology on the number of markers and the potential influence of the PCR amplification efficiency difference on accurate quantification are effectively avoided; meanwhile, the invention further develops a special data analysis algorithm which is used for processing sequencing data and accurately calculating the chimeric rate. A verification result shows that the scheme of the invention has excellent reliability and accuracy, and the detection sensitivity reaches the highest level of similar products on the current market. Therefore, the method has a wide application prospect in the fields needing micro chimera detection, such as hematopoietic stem cell transplantation, organ transplantation and the like.

A monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. A nucleic acid encoding the antibody or antigen-binding fragment thereof, an expression vector, a method for preparing the antibody, and use of the antibody in treatment of diseases or disorders associated with the human T cell receptor family. The generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention relates to a monoclonal humanized antibody or antigen-binding fragment thereof that specifically bind to the TRBV9 family of the human T cell receptor. The invention also relates to a nucleic acid encoding said antibody or antigen-binding fragment thereof, an expression vector, a method for preparing said antibody, and use of said antibody in treatment of diseases or disorders associated with the human T cell receptor family. The invention is directed to generation of antibodies that can be used for treating, in particular AS, celiac disease and malignant blood diseases, the pathogenesis of which involves the TRBV9 family TCRs.

The invention discloses a humanized osteoporosis mouse model and a construction method thereof, and belongs to the technical field of biotechnology and animal models. The invention aims at the core defects of large species difference, insufficient humanization degree, low pathological simulation degree, unstable phenotype and the like of the existing osteoporosis model. The humanized osteoporosis mouse model is constructed through five core steps of experimental animal pretreatment, collagen-nano hydroxyapatite bionic scaffold preparation and cell pre-implantation, immune-bone metabolism double-derived system construction, progressive osteoporosis induction and model identification and verification. According to the method, double-person origination of immune and bone metabolism systems is realized for the first time, the colonization rate and survival time of human cells are greatly improved, the pathological process of clinical postmenopausal osteoporosis is accurately simulated, the phenotype of the model is stable and uniform, the reactivity matching degree with clinical drugs is high, and the method can be widely applied to research and development of anti-osteoporosis drugs and research of pathological mechanisms.

The present application relates to the technical field of small molecule drugs, in particular to a isoquinoline drug and its application in improving or treating digestive tract tumors, and aims to provide a compound, a pharmaceutical composition containing the compound and its application in treating colorectal cancer and gastric cancer, and provides a 3,13-position substituted berberine derivative, the drug itself has less toxicity and does not affect the growth of normal human cells, and has a good application prospect in the development of novel antitumor drugs, especially in the development of anti-digestive tract tumor drugs.

An object of the present invention is to provide a cell population suitable for transplant of retinal tissue and a method of production thereof. The present invention provides a cell population for transplant, comprising retinal cells with a modified bipolar cell-regulating gene and a method of production thereof.

Provided are a recombinant collagen, an expression method and use thereof. In the present disclosure, the recombinant collagen is expressed by a human embryonic kidney cell Expi293F at a high protein expression level, thereby realizing the expression of a large-molecular-weight recombinant collagen. Activity studies have showed that the expressed recombinant collagen has desirable activity in promoting cell migration, while the recombinant collagen III+I with a fusion tag shows high stability at 4° C. In addition, cell activity studies have shown that the recombinant type III collagen expressed by human cells has better activity in promoting the cell migration than that of a commercially available type III collagen. These results indicate that the human cell expression system is conducive to the expression of highly active and large-molecular-weight recombinant collagen.

The present invention relates to a hybrid exosome formed by the fusion of a human cell-derived exosome and an artificial exosome. When an active ingredient labeled with a fluorescent material was attached or encapsulated in the hybrid exosome of the present invention and applied to cells, the active ingredient was observed in the cells. In addition, when the exosome was applied to skin tissue, fluorescence expression could also be observed in the dermal layer. Therefore, the hybrid exosome according to the present invention can be used as a novel drug delivery system.

The present disclosure provides methods of producing and expanding populations of B cells (e.g., human B cells for clinical applications). Such expanded populations can be used to produce B cell vaccines containing B cells that express 4-1BBL and are capable of promoting tumor cell death.

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and / or CD8 (e.g., CD8α and / or CD8β)), and / or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and / or MHC II β chains) and / or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

Provided are an AAV virus vector expressing an anti-VEGF fusion protein or antibody and a use of the AAV virus vector. Specifically, provided are a recombinant AAV virus vector comprising a nucleotide sequence encoding an anti-VEGF fusion protein or antibody, and a use of the recombinant AAV virus vector. The recombinant AAV virus exhibits an excellent infection effect in human cells and mouse cells, is stably and abundantly expressed within cells, and can effectively inhibit intraocular VEGF, and reduce leakage and angiogenesis caused by laser damage. Moreover, the AAV virus can be utilized to deliver an anti-VEGF fusion protein or an anti-VEGF antibody in the administration manner of subretinal injection, so that the objective of a single injection with long-term effectiveness is achieved; thus, the AAV virus can be used to prepare a drug for treating VEGF related diseases, and has broad market prospects.

Disclosed in the present invention is an siRNA for inhibiting the expression of a urate transporter 1 (URAT1) gene in human cells. In the present invention, a plurality of siRNAs capable of inhibiting URAT1 expression are obtained by screening, and on this basis, appropriate modifications are performed to obtain sequences with improved target silencing ability. Drugs with the siRNAs as active ingredients are expected to be clinically applicable in the prevention and treatment of diseases related to the URAT1 target, such as gout, hyperuricemia, gouty arthritis and renal calculi.

Multi-specific binding proteins that bind to and kill human cancer cells expressing epidermal growth factor receptor 2 (HER2 or ErbB2), but does not kill non-cancerous healthy human cells expressing HER2 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of HER2 expressing cancer. The invention also relates to multi-specific binding proteins that trigger CD8+ T cell killing of tumor cells.

This disclosure provides compositions and methods for the activation and expansion of human T cells or NK cells using soluble monospecific antibody complexes.

Hybrid hydrogels for organogenesis support organogenesis from mammalian cells, including human cells. The hybrid hydrogels typically include a network of crosslinked branched synthetic polymers including a branched polyalkylene oxide polymer and a thiolated extracellular matrix polymer, preferably hyaluronic acid. These polymers are crosslinked to adhesion ligand peptides. Also provided are methods of making the hybrid hydrogels and methods of using the hybrid hydrogels for organogenesis.

The present disclosure provides T cell receptors (TCRs) that bind to antigenic peptides of MAGE-A10 presented by HLA-A molecules. Also provided are nucleic acids encoding such TCRs, vectors comprising such nucleic acids, cells comprising such TCRs, nucleic acids and vectors, and compositions comprising such TCRs, nucleic acids, vectors, and cells. Also provided are methods for treating diseases / conditions using, and medical uses of, such TCRs, nucleic acids, vectors, cells and compositions.

The invention belongs to the technical field of antibody preparation, and particularly relates to an anti-human transcription factor PU.1 monoclonal antibody and application thereof. The amino acid sequences of CDR1-3 on a light chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.3-5, and the amino acid sequences of CDR1-3 on a heavy chain variable region of the monoclonal antibody are respectively shown as SEQ ID NO.8-10. The antibody provided by the invention can specifically and sensitively recognize the human transcription factor PU.1 expressed in human cells / tissues, has good affinity to the PU.1 and excellent anti-interference capability, and has no cross reaction to other species of homologous proteins, so that the accuracy and reliability of immunodetection of the human PU.1 can be improved, the coincidence degree of a detection result and an actual situation is improved, and the human transcription factor PU.1 can be effectively identified. False positive or false negative results are effectively avoided, and an effective antibody tool and a detection means are provided for high-specificity, high-accuracy and high-sensitivity detection of the PU.1 protein.

The invention provides a feeder cell for amplifying NK (Natural Killer) cells as well as a preparation method and application of the feeder cell. The feeder cell is a human cell with over-expression of IL-15, IL-21, 4-1BBL and IL-12p35 on a cell membrane. The human cells are selected from any one of immune cells, immortalized immune cells, lymphoma cells or leukemia cells. When the feeder cells are used for amplifying the NK cells, the amplification efficiency is high; the amplified NK cells are stronger in killing function; the feeder cell has very high clinical application value in amplification of the NK cells and large-scale clinical application of the NK cells.

Disclosed herein are compositions for engineering a human cell comprising a cell modulating agent or a vector encoding the cell modulating agent. Described herein are compositions comprising an engineered cell, wherein the engineered cell is an engineered human cell and comprises a modification such that the engineered cell is more resistant to an alkylating drug or a nucleoside analog relative to a non-engineered human cell. Various methods of treating a disease are provided, including, a method of treating cancer in a subject by administering the cell modulating agents and / or engineered cells as a therapeutic.

Provided are methods for treating colorectal cancer with an antibody that specifically binds to human Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4).